Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Grade I acute graft-vs-host disease: Treat or not?

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNikolaos KatsivelosFAFrancis AyukWHWilliam J. Hogan

Discussion

Loading...

Member takes

Overview

Observational analysis examines systemic treatment effects on acute graft-versus-host disease and non-relapse mortality.

Key Points

  • To analyze the effect of systemic treatment on outcomes in grade I acute graft-versus-host disease.
  • Evaluated clinical data and serum samples from patients with grade I acute GVHD across 24 centers.
  • Compared preemptive steroid treatment to a watch-and-wait approach.
  • Calculated Ann Arbor scores based on serum biomarkers.
  • Grade I GVHD diagnosed in 1143 patients, with 591 receiving preemptive treatment and 552 managed with watch-and-wait.
  • Preemptive steroid use did not reduce the risk of grade III/IV GVHD but increased non-relapse mortality.
  • AA scores effectively predicted progression to advanced GVHD and 12-month non-relapse mortality.

Cite This Study

Katsivelos et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e19ehttps://doi.org/10.1182/blood-2025-2461
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality2015 · 284 citations
  2. 2The Treatment of Steroid-Refractory Severe Gastrointestinal Acute Graft-Versus-Host Disease in Children after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre Experience2024
  3. 3Incidence, Risk Factors and Therapy Response of Acute Graft-versus-Host Disease after Postransplant Cyclophosphamide2024
  4. 4First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation2012 · 657 citations
  5. 5Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin2006 · 168 citations